ETH Zurich researchers have developed a gene switch that triggers insulin release in designer cells by playing music.
British CDMO Oxford Biomedica plc announces the expansion of its License and Supply Agreement with cell therapy specialist Cabaletta Bio, Inc. The new agreements adds CD19 as a new target – it originally covered Cabaletta Bio’s lead product, DSG3-CAART.
Oil-eating bacteria form dendritic biofilms that reshape oil droplets to speed up the rate of consumption
French vaccine maker Valneva SE will double the amount of a US$100m debt financing granted by Deerfield Management Company and OrbiMed.
Basel- and Heidelberg-based CDMO Celonic Group has appointed Dr Samanta Cimitan as Chief Executive Officer (CEO).
Swiss Spexis AG has announced a US$2.5m capital commitment to fund a two-part pivotal Phase III study to get market approval for its inhaled cystic fibrosis antibiotic colistimethate sodium.
With a US$1bn acquisition of Canadian Inversago Pharma, Novo Nordisk A/S fiights to maintain its dominant position in the booming weight loss drug market.
British researchers have proven that a new gene can prevent progression of hereditary kidney damage in mice.
Lipid, nutrition and frozen bakery specialist Allianza Team puts £900,500 into pre-Series A financing of microbial palm oil producer Clean Food Group Ltd.
A Dutch-German team of researchers has found out that the amount of not degradable plastics is lower than estimated but that they persist for longer than previously assumed.